
Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Advertisement
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Researchers are launching a new clinical trial that will evaluate the combination of glofitamab with pirtobrutinib in MCL.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Updated results from the phase 3 ECHO trial were presented at ASH 2024.
Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Acalabrutinib, umbralisib, and ublituximab treatment is effective in patients with de novo MCL, with a 100% CR rate.
A team of researchers investigated this mechanism of therapy resistance specifically to CD19-directed CAR T-cell therapy.
The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease.
The results from a phase I seamless design study are relevant especially to older patients and those with high-risk disease.
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters: